Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653443 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study
A Phase 2 study, sponsored by Cerus Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02653443: Clinical Trial Phase 2 study, sponsored by Cerus Corporation.
NCT02653443 is a Phase 2 study that was terminated before completion, run by Cerus Corporation. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02653443, a Phase 2 study, was terminated before completion, sponsored by Cerus Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The objective of this study is to test the hypothesis that INTERCEPT Blood System for platelet components stored for 6 or 7 days after INTERCEPT Blood System treatment retain sufficient viability for therapeutic efficacy. The post-infusion recovery and lifespan of autologous INTERCEPT Blood System for platelet components in 35% plasma/65% InterSol (Test platelets) stored for 6 or 7 days will be measured in comparison to "fresh" autologous radiolabeled platelets (Control platelets) according to FDA guidance for platelet testing (FDA 1999). Recovery and lifespan results between components stored for 6 and 7 days will also be assessed.
Interventions
- BIOLOGICAL Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.
- BIOLOGICAL Autologous apheresis Conventional untreated Platelet Components
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Why NCT02653443 stopped before completion
NCT02653443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. is the first listed.
NCT02653443 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02653443 about?
NCT02653443 is a clinical study titled "A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study". The objective of this study is to test the hypothesis that INTERCEPT Blood System for platelet components stored for 6 or 7 days after INTERCEPT Blood System treatment retain sufficient viability for therapeutic efficacy. The post-infusion recovery and lifespan of autologous INTERCEPT Blood System f...
What is the current status of trial NCT02653443?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2015-12. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02653443?
The interventions under investigation include: Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. (BIOLOGICAL), Autologous apheresis Conventional untreated Platelet Components (BIOLOGICAL).
Who is sponsoring clinical trial NCT02653443?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02653443's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia